why choose us

First received: December 15, 2022

Clinical Trial: Efficacy and Safety of Infliximab Biosimilar in Treatment of Resistant Hidradenitis Suppurativa

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Hidradenitis Suppurativa

Study Type: Interventional


Official Title: Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa

Brief Summary: The aim of this clinical trial is to assess the efficacy and safety of Infliximab biosimilar in patients of resistant Hidradenitis suppurativa. The main question it aims to answer are:how effective is infliximab biosimilar in treating resistant Hidradentis suppurativaIs infliximab biosimilar safe in these patients Patients will receive weekly injections of Infliximab Biosimilar Remsima, according to weight, for first 4 weeks, and then fortnightly for next 10 weeks. Patients will be followed up for 10 weeks post…

Read more